Generics Bulletin Podcasts
The Generics Bulletin Podcast examines the trends and decisions shaping the global generics and biosimilars industry. Aimed at industry professionals, it features specialist reporters and expert voices discussing regulatory shifts, pricing pressures, market access, and competitive dynamics. Episodes are published bi-monthly and include insights from key industry conferences. It is produced by Norstella/Citeline and provides updates for those following the generics and biosimilars sector.
Episodes
Off-Patent, On Record: Navigating The Financial Strategy Behind Litigation With Sandoz’s Julia Pike
In the third episode of Off-Patent, On Record, Generics Bulletin’s senior reporter Urtė Fultinavičiūtė is joined by Sandoz’s head of IP Julia Pike to analyze the European intellectual property system, how it compares to the US, and the financial decisions behind litigation for off-patent companies.
For any podcast feedback or queries, you can now reach us at podcasts@norstella.com.
The Generics Bulletin Podcast: Discussing Sandoz’s Strategy Updates As It Prepares For A Biosimilars Boom
On September 8, Sandoz revealed a slew of strategy updates and forecasts at a capital markets day at the London Stock Exchange. Generics Bulletin editor Dave Wallace was there, and discusses the key details with deputy editor Dean Rudge.
Off-Patent, On Record: A Story Of Patients Fighting For Accessible Cystic Fibrosis Treatment
In the second episode of Off-Patent, On Record, Generics Bulletin’s senior reporter Urtė Fultinavičiūtė hears how patients with cystic fibrosis travelled to Bangladesh to collect generic version of Vertex’s highly inaccessible Trikafta. Urtė is joined by Wilna Lottering and her son Josh from South Africa, as well as Gayle Pledger, a cystic fibrosis campaigner.
Generic Bulletin Trailer
Off-Patent, On Record: View Through The Journalist's Lens With Generics Bulletin's Dave Wallace
Generics Bulletin’s senior reporter Urtė Fultinavičiūtė launches a new interview podcast series “Off-Patent, On Record.” In the inaugural episode, Urtė is joined by Dave Wallace, executive editor at Generics Bulletin, who has been covering the off-patent drug industry as a journalist and editor for 16 years.
The Next Era Of Oncology Biosimilars
Oncology biosimilars have already helped expand access to established biologic treatments while supporting more sustainable healthcare spending. As the market moves towards increasingly complex therapies, however, identifying viable opportunities will require more than monitoring patent expiries.
In this podcast, ICON experts Colin Farquharson and Martin Lachs, discuss how scientific innovation,
The Generics Bulletin Podcast: Summer Conferences
Generics Bulletin's editorial team discusses the recent Medicines for Europe legal and annual conferences, attended by executive editor Dave Wallace, as well as the Medicines UK conference attended by reporter Anabel Costa-Ferreira.
The Generics Bulletin Podcast: Probing The Patent Monopoly With I-MAK’s Tahir Amin
The Generics Bulletin Podcast: Probing The Patent Monopoly With I-MAK’s Tahir Amin
Description: Generics Bulletin senior reporter Urtė Fultinavičiūtė talks to Tahir Amin, co-founder and CEO of I-MAK, about the current intellectual property system that curtails off-patent drug competition and global health equity.
The Generics Bulletin Podcast: Biosimilars Conference Report And Big M&A Deals
Generics Bulletin's editorial team discusses the recent Medicines for Europe biosimilars conference, attended by deputy editor Dean Rudge; while editor Dave Wallace talks about the latest big deals in biosimilars and what is behind them.
